A functional and comparative approach for the study of Wolbachia-mediated virus blocking in Aedes aegypti and Aedes albopictus
研究沃尔巴克氏体介导的埃及伊蚊和白纹伊蚊病毒阻断的功能和比较方法
基本信息
- 批准号:10455257
- 负责人:
- 金额:$ 49.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-04 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AedesAntibodiesAntiviral AgentsAsian AmericansAustraliaBacteriaBiocontrolsBrazilCandidate Disease GeneCell AdhesionCellular StressChikungunya virusColombiaCommunitiesCulicidaeDataDengueDengue FeverDengue InfectionDengue VirusDevelopmentDrug or chemical Tissue DistributionEffectivenessFutureGardenalGenesGeneticGenetic TranscriptionGenetic VariationGenomeGenotypeGeographyGoalsGovernmentHealthHumanImmuneIncidenceIndonesiaInfectionInheritedInsectaKnowledgeLaboratoriesLocationMalaysiaMediatingMexicoModelingNatureNeuronsOutcomePopulationPopulation HeterogeneityPrivatizationProcessProteinsRNA InterferenceReactive Oxygen SpeciesReporterResearchResistanceResourcesRiskRoleSingaporeSisterSiteTestingTimeTissuesUrbanizationVaccinesVariantVietnamViralVirusVirus ReplicationWolbachiaYellow FeverYellow fever virusZIKAZika Viruschikungunyaclimate changecomparativedensitydesignendosymbiontexperienceexperimental studygeographically distanthuman diseaseimprovedmosquito reproductionnovelprogramsregional differenceresponsesymbionttheoriestraittransmission processvectorvector competencevector controlvector mosquitoviral transmissionvirus geneticsvirus host interactionweapons
项目摘要
PROJECT SUMMARY/ABSTRACT
The global range of the mosquito, Aedes aegypti continues to expand due to a changing climate and
increasing urbanization. As Ae. aegypti is the primary vector of dengue, Zika, yellow fever and
chikungunya viruses, these range shifts also increase the risk of human disease. With few effective
vaccines or antiviral drugs, vector control remains the best weapon against mosquitoes. Recently, the
release of an insect endosymbiont, Wolbachia, into mosquito populations has emerged as a novel
biocontrol strategy. Maternally inherited and with inbuilt genetic drive, Wolbachia tends to spread
through insect populations. Inside the mosquito, the bacterium limits the replication of viruses, a trait
called ‘viral blocking’. Following release of Wolbachia into wild populations, the viral blocking effect is
leading to substantial reductions in the incidence of dengue fever in humans. One concern for the long-
term efficacy of Wolbachia is the emergence of resistance in mosquitoes or viruses. To design
strategies to counter this likely scenario, we need to understand the genetic basis of viral blocking.
While many theories have been proposed, none have been entirely satisfying. Recently, the McGraw
lab used a selection experiment to create Ae. aegypti lines carrying Wolbachia with differences in
blocking. In sequencing those lines, her group identified a set of novel candidate loci and a new set of
hypotheses for the basis of blocking. This study also demonstrated that the strength of blocking is likely
to vary across diverse mosquito genetic backgrounds. Here we propose to provide functional testing
for the candidate blocking genes involved with cell adhesion, transcriptional pausing and neuronal
function, for both dengue and chikungunya viruses using RNA silencing. In these experiments we will
also contrast Aedes albopictus, that has long harbored a natural infection of Wolbachia, against Ae.
aegypti with a recently artificially introduced Wolbachia. The nature of blocking in Ae. albopictus is a
likely harbinger of the future of blocking in the artificially infected species. We will also carry out large
common garden experiments to dissect the relative contribution of regional differences in mosquito and
virus diversity to the strength of blocking. This project will produce novel resources for the community
including a new Wolbachia infected Ae. aegypti line, a set of antibodies against key blocking association
proteins and data on the efficacy of improved fluorescent reporter viruses for the study of vector
competence. More broadly, this research will help to test a revised model for Wolbachia-mediated viral
blocking – knowledge fundamental for designing strategies to prolong Wolbachia’s efficacy in the field.
It will also reveal the robustness of blocking to mosquito and viral genetic diversity, that will inform
strategies for future Wolbachia strain deployment globally.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elizabeth Ann McGraw其他文献
Elizabeth Ann McGraw的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elizabeth Ann McGraw', 18)}}的其他基金
Exploring the coevolutionary potential of chikungunya virus and its Aedes mosquito vectors
探索基孔肯雅病毒及其伊蚊媒介的共同进化潜力
- 批准号:
10711906 - 财政年份:2023
- 资助金额:
$ 49.18万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 49.18万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 49.18万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 49.18万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 49.18万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 49.18万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 49.18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 49.18万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 49.18万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 49.18万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 49.18万 - 项目类别: